Ligand Binding Assay Comprehensive Study by Type (Antigen Discovery Inc, Radioactive, Non-Radioactive), Application (Biomedical Research, Drug Discovery, Others) Players and Region - Global Market Outlook to 2030

Ligand Binding Assay Market by XX Submarkets | Forecast Years 2024-2030  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Ligand Binding Assay
Ligand binding assays (LBA) are analytical procedures to quantify an analyte (macromolecule) based on its affinity for a ligand, including but not limited to antibodies, antigens, receptors, oligonucleotides, and peptides. There are various types of ligand binding assays, both radioactive and non-radioactive. As such, ligand binding assays are a superset of radio binding assays, that are the conceptual inverse of radioimmunoassay (RIA). Some newer sorts are referred to as "mix-and-measure" assays because they do not require separation of sure from unbound substance binding assays and are used primarily in pharmacology for varied demands. Specifically, despite the human body's endogenous receptors, hormones, and other neurotransmitters, pharmacologists utilize assays so as to form medicine that are selective or mimic, the endogenously found cellular components. On the opposite hand, such techniques also are available to create receptor antagonists so as to prevent cascades. Such advances offer researchers the power not solely to quantify hormones and hormone receptors but also to contribute vital pharmacological data in drug development and treatment plans.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing on production technologies, efficiency enhancement, and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge investment in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Ligand Binding Assay market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sygnature Discovery (United Kingdom), Shanghai Medicilon Inc (China), Intertek Group plc (United Kingdom), PerkinElmer Inc (United States), Charles River (United States), Alliance Pharma (United Kingdom), Eurofins Discovery (United States), Creative Biogene (United States), IBR Inc (United States), LGC Limited (United Kingdom) and Accelero Bioanalytics GmbH (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Ligand Binding Assay market by Type (Antigen Discovery Inc, Radioactive and Non-Radioactive), Application (Biomedical Research, Drug Discovery and Others) and Region.



On the basis of geography, the market of Ligand Binding Assay has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increasing Adoption by the Biomedical Research

Market Growth Drivers:
Increasing need to detect the anti-drug antibodies in biological matrices

Challenges:
Lack of awareness and Lack of skilled labor

Restraints:
High cost of the procedures

Opportunities:
Increased research and development activities and Rapid development activities

Market Leaders and their expansionary development strategies

In January 2020, Birmingham-based preclinical contract research organization, Gifford Bioscience Limited, launched its new SPR Biacore Assay Service. This is a highly specialized technique.


Key Target Audience
Supplier of Ligand Binding Assay, Governmental and Regulatory bodies and End-Users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Antigen Discovery Inc
  • Radioactive
  • Non-Radioactive
By Application
  • Biomedical Research
  • Drug Discovery
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing need to detect the anti-drug antibodies in biological matrices
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness
      • 3.3.2. Lack of skilled labor
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption by the Biomedical Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ligand Binding Assay, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Ligand Binding Assay (Value)
      • 5.2.1. Global Ligand Binding Assay by: Type (Value)
        • 5.2.1.1. Antigen Discovery Inc
        • 5.2.1.2. Radioactive
        • 5.2.1.3. Non-Radioactive
      • 5.2.2. Global Ligand Binding Assay by: Application (Value)
        • 5.2.2.1. Biomedical Research
        • 5.2.2.2. Drug Discovery
        • 5.2.2.3. Others
      • 5.2.3. Global Ligand Binding Assay Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Ligand Binding Assay: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sygnature Discovery (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shanghai Medicilon Inc (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Intertek Group plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PerkinElmer Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Charles River (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alliance Pharma (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eurofins Discovery (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Creative Biogene (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. IBR Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. LGC Limited (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Accelero Bioanalytics GmbH (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Ligand Binding Assay Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Ligand Binding Assay (Value)
      • 7.2.1. Global Ligand Binding Assay by: Type (Value)
        • 7.2.1.1. Antigen Discovery Inc
        • 7.2.1.2. Radioactive
        • 7.2.1.3. Non-Radioactive
      • 7.2.2. Global Ligand Binding Assay by: Application (Value)
        • 7.2.2.1. Biomedical Research
        • 7.2.2.2. Drug Discovery
        • 7.2.2.3. Others
      • 7.2.3. Global Ligand Binding Assay Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ligand Binding Assay: by Type(USD Million)
  • Table 2. Ligand Binding Assay Antigen Discovery Inc , by Region USD Million (2018-2023)
  • Table 3. Ligand Binding Assay Radioactive , by Region USD Million (2018-2023)
  • Table 4. Ligand Binding Assay Non-Radioactive , by Region USD Million (2018-2023)
  • Table 5. Ligand Binding Assay: by Application(USD Million)
  • Table 6. Ligand Binding Assay Biomedical Research , by Region USD Million (2018-2023)
  • Table 7. Ligand Binding Assay Drug Discovery , by Region USD Million (2018-2023)
  • Table 8. Ligand Binding Assay Others , by Region USD Million (2018-2023)
  • Table 9. South America Ligand Binding Assay, by Country USD Million (2018-2023)
  • Table 10. South America Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 11. South America Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 12. Brazil Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 13. Brazil Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 14. Argentina Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 15. Argentina Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 16. Rest of South America Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 17. Rest of South America Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 18. Asia Pacific Ligand Binding Assay, by Country USD Million (2018-2023)
  • Table 19. Asia Pacific Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 20. Asia Pacific Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 21. China Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 22. China Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 23. Japan Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 24. Japan Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 25. India Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 26. India Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 27. South Korea Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 28. South Korea Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 29. Taiwan Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 30. Taiwan Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 31. Australia Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 32. Australia Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 35. Europe Ligand Binding Assay, by Country USD Million (2018-2023)
  • Table 36. Europe Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 37. Europe Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 38. Germany Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 39. Germany Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 40. France Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 41. France Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 42. Italy Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 43. Italy Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 44. United Kingdom Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 45. United Kingdom Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 46. Netherlands Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 47. Netherlands Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 48. Rest of Europe Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 49. Rest of Europe Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 50. MEA Ligand Binding Assay, by Country USD Million (2018-2023)
  • Table 51. MEA Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 52. MEA Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 53. Middle East Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 54. Middle East Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 55. Africa Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 56. Africa Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 57. North America Ligand Binding Assay, by Country USD Million (2018-2023)
  • Table 58. North America Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 59. North America Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 60. United States Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 61. United States Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 62. Canada Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 63. Canada Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 64. Mexico Ligand Binding Assay, by Type USD Million (2018-2023)
  • Table 65. Mexico Ligand Binding Assay, by Application USD Million (2018-2023)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Ligand Binding Assay: by Type(USD Million)
  • Table 78. Ligand Binding Assay Antigen Discovery Inc , by Region USD Million (2025-2030)
  • Table 79. Ligand Binding Assay Radioactive , by Region USD Million (2025-2030)
  • Table 80. Ligand Binding Assay Non-Radioactive , by Region USD Million (2025-2030)
  • Table 81. Ligand Binding Assay: by Application(USD Million)
  • Table 82. Ligand Binding Assay Biomedical Research , by Region USD Million (2025-2030)
  • Table 83. Ligand Binding Assay Drug Discovery , by Region USD Million (2025-2030)
  • Table 84. Ligand Binding Assay Others , by Region USD Million (2025-2030)
  • Table 85. South America Ligand Binding Assay, by Country USD Million (2025-2030)
  • Table 86. South America Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 87. South America Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 88. Brazil Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 89. Brazil Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 90. Argentina Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 91. Argentina Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 92. Rest of South America Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 93. Rest of South America Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 94. Asia Pacific Ligand Binding Assay, by Country USD Million (2025-2030)
  • Table 95. Asia Pacific Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 96. Asia Pacific Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 97. China Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 98. China Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 99. Japan Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 100. Japan Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 101. India Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 102. India Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 103. South Korea Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 104. South Korea Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 105. Taiwan Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 106. Taiwan Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 107. Australia Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 108. Australia Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 110. Rest of Asia-Pacific Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 111. Europe Ligand Binding Assay, by Country USD Million (2025-2030)
  • Table 112. Europe Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 113. Europe Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 114. Germany Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 115. Germany Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 116. France Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 117. France Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 118. Italy Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 119. Italy Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 120. United Kingdom Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 121. United Kingdom Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 122. Netherlands Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 123. Netherlands Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 124. Rest of Europe Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 125. Rest of Europe Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 126. MEA Ligand Binding Assay, by Country USD Million (2025-2030)
  • Table 127. MEA Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 128. MEA Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 129. Middle East Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 130. Middle East Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 131. Africa Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 132. Africa Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 133. North America Ligand Binding Assay, by Country USD Million (2025-2030)
  • Table 134. North America Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 135. North America Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 136. United States Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 137. United States Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 138. Canada Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 139. Canada Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 140. Mexico Ligand Binding Assay, by Type USD Million (2025-2030)
  • Table 141. Mexico Ligand Binding Assay, by Application USD Million (2025-2030)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ligand Binding Assay: by Type USD Million (2018-2023)
  • Figure 5. Global Ligand Binding Assay: by Application USD Million (2018-2023)
  • Figure 6. South America Ligand Binding Assay Share (%), by Country
  • Figure 7. Asia Pacific Ligand Binding Assay Share (%), by Country
  • Figure 8. Europe Ligand Binding Assay Share (%), by Country
  • Figure 9. MEA Ligand Binding Assay Share (%), by Country
  • Figure 10. North America Ligand Binding Assay Share (%), by Country
  • Figure 11. Global Ligand Binding Assay share by Players 2023 (%)
  • Figure 12. Global Ligand Binding Assay share by Players (Top 3) 2023(%)
  • Figure 13. Global Ligand Binding Assay share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Sygnature Discovery (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Sygnature Discovery (United Kingdom) Revenue: by Geography 2023
  • Figure 17. Shanghai Medicilon Inc (China) Revenue, Net Income and Gross profit
  • Figure 18. Shanghai Medicilon Inc (China) Revenue: by Geography 2023
  • Figure 19. Intertek Group plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Intertek Group plc (United Kingdom) Revenue: by Geography 2023
  • Figure 21. PerkinElmer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 22. PerkinElmer Inc (United States) Revenue: by Geography 2023
  • Figure 23. Charles River (United States) Revenue, Net Income and Gross profit
  • Figure 24. Charles River (United States) Revenue: by Geography 2023
  • Figure 25. Alliance Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Alliance Pharma (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Eurofins Discovery (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eurofins Discovery (United States) Revenue: by Geography 2023
  • Figure 29. Creative Biogene (United States) Revenue, Net Income and Gross profit
  • Figure 30. Creative Biogene (United States) Revenue: by Geography 2023
  • Figure 31. IBR Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. IBR Inc (United States) Revenue: by Geography 2023
  • Figure 33. LGC Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. LGC Limited (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Accelero Bioanalytics GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Accelero Bioanalytics GmbH (Germany) Revenue: by Geography 2023
  • Figure 37. Global Ligand Binding Assay: by Type USD Million (2025-2030)
  • Figure 38. Global Ligand Binding Assay: by Application USD Million (2025-2030)
  • Figure 39. South America Ligand Binding Assay Share (%), by Country
  • Figure 40. Asia Pacific Ligand Binding Assay Share (%), by Country
  • Figure 41. Europe Ligand Binding Assay Share (%), by Country
  • Figure 42. MEA Ligand Binding Assay Share (%), by Country
  • Figure 43. North America Ligand Binding Assay Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sygnature Discovery (United Kingdom)
  • Shanghai Medicilon Inc (China)
  • Intertek Group plc (United Kingdom)
  • PerkinElmer Inc (United States)
  • Charles River (United States)
  • Alliance Pharma (United Kingdom)
  • Eurofins Discovery (United States)
  • Creative Biogene (United States)
  • IBR Inc (United States)
  • LGC Limited (United Kingdom)
  • Accelero Bioanalytics GmbH (Germany)
Select User Access Type

Key Highlights of Report


Feb 2024 187 Pages 50 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sygnature Discovery (United Kingdom), Shanghai Medicilon Inc (China), Intertek Group plc (United Kingdom), PerkinElmer Inc (United States), Charles River (United States), Alliance Pharma (United Kingdom), Eurofins Discovery (United States), Creative Biogene (United States), IBR Inc (United States), LGC Limited (United Kingdom) and Accelero Bioanalytics GmbH (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Adoption by the Biomedical Research" is seen as one of major influencing trends for Ligand Binding Assay Market during projected period 2023-2030.
The Ligand Binding Assay market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Ligand Binding Assay Market Report?